Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.40 |
| ▸ | CNR2 | P34972 | 11/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131694 | 0.93 | KCNQ3 (0.36) | CNR1CNR2KCNQ3KCNQ2 | |
| SCHEMBL4125753 | 0.92 | CNR1 (0.34) | CNR1CNR2P2RX7KCNQ3KCNQ2 | |
| SCHEMBL4136940 | 0.91 | KCNQ3 (0.34) | CNR1CNR2P2RX7KCNQ3KCNQ2 | |
| SCHEMBL4130718 | 0.90 | KCNQ3 (0.34) | CNR1CNR2P2RX7KCNQ3KCNQ2 | |
| SCHEMBL4123908 | 0.90 | SMN1; SMN2 (0.37) | P2RX7KCNQ3KCNQ2 | |
| SCHEMBL4135601 | 0.86 | SMN1; SMN2 (0.34) | KCNQ3KCNQ2 | |
| SCHEMBL4127374 | 0.86 | SCN9A (0.37) | CNR1CNR2P2RX7KCNQ3KCNQ2 | |
| SCHEMBL4126946 | 0.86 | KCNQ3 (0.35) | P2RX7KCNQ3KCNQ2 | |
| SCHEMBL4130354 | 0.86 | RXRA (0.32) | CNR1CNR2KCNQ3KCNQ2 | |
| SCHEMBL4123630 | 0.85 | MDM2 (0.38) | KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | CNR1 938/4885CNR2 820/4885P2RX7 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.